Steffen Goletz founded Glycotope in 2001 and has more than 16 years of experience in the life sciences industry. Prior to this, he worked for several renowned research institutions, including the Max Delbrueck Centre for Molecular Medicine (Berlin), the MRC Centre for Protein Engineering (Cambridge, UK) and the German Cancer Research Centre in Heidelberg. As CSO, he is responsible for the development of Glycotope’s platform technologies and product pipeline of glycooptimized biotherapeutics. He studied biology, biochemistry and molecular biology at the universities in Heidelberg, Kaiserslautern, Manchester (UK) and Berlin and holds a PhD in Biochemistry from Freie Universiät, Berlin. Steffen Goletz founded Glycotope in 2001 and has more than 16 years of experience in the life sciences industry. Prior to this, he worked for several renowned research institutions, including the Max Delbrueck Centre for Molecular Medicine (Berlin), the MRC Centre for Protein Engineering (Cambridge, UK) and the German Cancer Research Centre in Heidelberg. As CSO, he is responsible for the development of Glycotope’s platform technologies and product pipeline of glycooptimized biotherapeutics. He studied biology, biochemistry and molecular biology at the universities in Heidelberg, Kaiserslautern, Manchester (UK) and Berlin and holds a PhD in Biochemistry from Freie Universiät, Berlin.

Biochemistry